Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 11/20 | 0.40 |
| ▸ | GIPR | P48546 | 9/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | MRE11 | P49959 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585392 | 0.90 | RXRA (0.42) | GCGRGIPRSTAT3MRE11CPB1 | |
| SCHEMBL6000638 | 0.90 | RXRA (0.42) | GCGRGIPRSTAT3MRE11CPB1 | |
| SCHEMBL5585253 | 0.90 | CA1 (0.41) | NR1H4STAT3MRE11CPB1TRPA1 | |
| SCHEMBL5585530 | 0.90 | LMNA (0.42) | MRE11ALDH1A1SMN1; SMN2MEN1LMNA | |
| SCHEMBL5585724 | 0.90 | MRE11 (0.38) | GCGRGIPRSTAT3MRE11CPB1 | |
| Hydrochloric Acid SCHEMBL5585448 | 0.89 | RXRA (0.41) | GCGRGIPRSTAT3MRE11CPB1 | |
| SCHEMBL5585241 | 0.89 | RXRA (0.41) | GCGRGIPRSTAT3MRE11CPB1 | |
| SCHEMBL5585528 | 0.89 | RXRA (0.41) | GCGRGIPRSTAT3MRE11CPB1 | |
| SCHEMBL5585463 | 0.89 | RXRA (0.43) | GCGRGIPRMRE11CPB1ALDH1A1 | |
| Potassium Ion SCHEMBL5585240 | 0.89 | GCGR (0.39) | GCGRGIPRSTAT3MRE11CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | NR1H4 302/4885GCGR 317/4885GIPR 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.